Global Anticoagulant Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Anticoagulant Market is presumed to reach the market size of nearly USD 89.95 Billion by 2032 from USD 40.1 Billion in 2023 with a CAGR of 9.39% under the study period 2024-2032.

Anticoagulants, generally called blood thinners, are chemical materials that prohibit or curtail coagulation of blood and lengthen the clotting period. Anticoagulants are used to abolish the chances of blood clots in the body. Blood clots are built when platelets glue together and proteins present in the blood bind together to create a solid lump. Anticoagulants cease the platelets from binding to one another and clotting proteins from adhering together. The market offers various types of anticoagulant drugs, and each drug functions by deterring various paths of blood coagulation. These drugs are primarily used for the high threat of blood clots, deep vein thrombosis, pulmonary embolism, and others. Besides, they are commonly used in the treatment of pulmonary embolism, atrial fibrillation, and managing the risk of stroke.

MARKET DYNAMICS

The global anticoagulants market is anticipated to grow at a substantial rate in the coming years, with the increasing plurality of diseases such as venous thromboembolism and cardiovascular disease across the globe. Moreover, the growing adoption of new oral anticoagulants, and maturing awareness of new techniques is boosting the market growth. Similarly, expanding obesity problems and geriatric population with the growing demand for contemporary therapeutics are predicted to affect the growth of the global anticoagulant market during the forecast period.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anticoagulant. The growth and trends of Anticoagulant industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Anticoagulant market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Category

Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa)
Vitamin K Antagonist
Direct Thrombin Inhibitors
Heparin and Low Molecular Weight Heparin (LMWH)
Others

By Route of Administration

Oral Anticoagulants
Injectable Anticoagulants

By Application

Atrial Fibrillation/Myocardial Infarction (Heart Attack)
Deep Vein Thrombosis (DVT)
Pulmonary Embolism
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anticoagulant market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anticoagulant market include Aspen Holdings, Pfizer Inc., Bristol-Myers Squibb Company, GSK Plc, Sanofi, Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Eisai Co. Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11211613

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. ANTICOAGULANT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Category
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY DRUG CATEGORY

5.1. Overview By Drug Category
5.2. Historical and Forecast Data
5.3. Analysis By Drug Category
5.4. Novel Oral Anticoagulants (NOACs) (Eliquis, Xarelto, Savaysa & Lixiana, Pradaxa) Historic and Forecast Sales By Regions
5.5. Vitamin K Antagonist Historic and Forecast Sales By Regions
5.6. Direct Thrombin Inhibitors Historic and Forecast Sales By Regions
5.7. Heparin and Low Molecular Weight Heparin (LMWH) Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data
6.3. Analysis By Route of Administration
6.4. Oral Anticoagulants Historic and Forecast Sales By Regions
6.5. Injectable Anticoagulants Historic and Forecast Sales By Regions

7. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data
7.3. Analysis By Application
7.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack) Historic and Forecast Sales By Regions
7.5. Deep Vein Thrombosis (DVT) Historic and Forecast Sales By Regions
7.6. Pulmonary Embolism Historic and Forecast Sales By Regions
7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL ANTICOAGULANT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ANTICOAGULANT COMPANIES

9.1. Anticoagulant Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF ANTICOAGULANT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Aspen Holdings
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Pfizer Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Bristol-Myers Squibb Company
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. GSK Plc
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Sanofi
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Bayer AG
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Boehringer Ingelheim International GmbH
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Daiichi Sankyo Company Limited
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Johnson & Johnson Services Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Eisai Co. Ltd
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies